Effect of Bufei Huaxian Decoction combined with prednisone on idiopathic pulmonary fibrosis

摘要

cqvip:Objective:To explore the therapeutic effect of Bufei Huaxian Decoction plus prednisone on patients with idiopathic pulmonary fibrosis. Methods:80 patients with idiopathic pulmonary fibrosis treated in our hospital from January 2018 to January 2019 were randomly divided into prednisone group and combination group, 40 cases in each group. Prenisone group was treated with prednisone, while Bufei Huaxian Decoction plus prednisone was used in combination group. Maximum expiratory flow (PEF), forced expiratory volume (FEV1) and forced vital capacity (FVC) were measured. Hyaluronidase (HA), laminin (LN), procollagen type Ⅲ (PCIII), transforming growth factor-β1 (TGF-β1) and hypersensitive C-reactive eggs were detected by enzyme-linked immunosorbent assay (ELISA). The levels of hs-CRP, TNF-α and glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), malondialdehyde (MDA) were measured by immunoturbidimetry. The levels of T lymphocyte subsets and therapeutic effects were compared between the two groups. Results:After treatment, the levels of PEF, FEV1 and FVC in the combined group were higher than those in the prednisone group (P<0.05). After treatment, the levels of HA, LN and PC-Ⅲ in the combined group were lower than those in the prednisone group (P<0.05). After treatment, the serum levels of TGF-β1, hs-CRP and TNF-α in the combined group were lower than those in the prednisone group (P<0.05). After treatment, the serum GSH-Px and SOD levels in the combined group were higher than those in the prednisone group, and MDA levels were lower than those in the prednisone group (P<0.05). After treatment, the levels of CD8 + in the combined group were lower than those in the prednisone group, and the levels of CD4 + and CD3 + were higher than those in the prednisone group (P<0.05). The total effective rate of combined group 95.00% was higher than that of prednisone group 80.00% (P<0.05). Conclusions:Bufei Huaxian Decoction plus prednisone can improve the pulmonary function of patients with idiopathic pulmonary fibrosis, reduce the severity of pulmonary fibrosis, and enhance the antioxidant capacity and immune function of patients. The therapeutic effect is remarkable.